MedTrace Logo

Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection

NCT04973943 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-07-22

No results posted yet for this study

Summary

FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain. Our main objective is to test donor-derived Cell-Free DNA (dd-cfDNA) against endomyocardial biopsy (EMB) for the diagnosis of acute cellular rejection.

Conditions

  • Heart Transplant Rejection

Interventions

DIAGNOSTIC_TEST

Donor-derived cell Free DNA

Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously

Sponsors & Collaborators

  • Puerta de Hierro University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-19
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04973943 on ClinicalTrials.gov